![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||
![]() |
|||||
|
|||||
![]() |
|||||
![]() |
|||||
![]() |
![]() |
Dostinex The Sex Drug |
![]() |
Dostinex Medical Uses |
![]() |
Dostinex Medical References |
![]() |
Dostinex vs. Parlodel (Bromocriptine) | ![]() |
Buy Dostinex | ![]() |
![]() |
![]() |
![]() |
![]() |
"Dostinex has been approved for the
treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas (tumors).
Dostinex has been very successful in treating hyperprolactinemia and has been proved much more successful
in doing so than Parlodel (Bromocriptine )"
"Cabergoline (Dostinex) was tolerated
satisfactorily by all our patients. The results have confirmed a high efficacy and a very good tolerability
of Cabergoline (Dostinex) in the treatment of patients with pituitary adenomas. Together with a very
convenient administration, such therapy can provide a very good patient compliance thus should be
considered the first line option in patients with prolactinomas" |
|
![]() |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
"…in giant, aggressive prolactinomas, cabergoline (Dostinex) represents a first-line therapy effective in reducing PRL levels and determining tumour shrinkage." Corsello
SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA, Colosimo C.
"These data indicate that cabergoline is a very effective agent for lowering the prolactin levels in hyperprolactinemic patients and that it appears to offer considerable advantage over Bromocriptine in terms of efficacy and tolerability" Sabuncu
T, Arikan E, Tasan E, Hatemi H.
"Given
that these patients had advanced disease which makes it difficult to find
significant therapeutic effects, medical therapy with potent dopamine
agonists such as cabergoline (Dostinex) may evolve as a novel therapeutic
option in a subgroup of patients with clinically nonfunctioning tumours
declining operation and radiotherapy" ![]() |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() "Cabergoline
(Dostinex) was shown to be significantly more effective than Bromocriptine
in inducing a complete biochemical response and clinical efficacy
and was better tolerated than Bromocriptine in the majority of patients.
Notable tumour shrinkage until tumour disappearance was observed
during cabergoline treatment in most patients with macroprolactinoma
and it was also proven effective in patients resistant to or with
a poor response to Bromocriptine …
"These data indicate that cabergoline is a very effective agent for lowering the prolactin levels in hyperprolactinemic patients and that it appears to offer considerable advantage over Bromocriptine in terms of efficacy and tolerability" Sabuncu
T, Arikan E, Tasan E, Hatemi H. "Dostinex has been approved for the
treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas (tumors).
Dostinex has been very successful in treating hyperprolactinemia and has been proved much more successful
in doing so than Parlodel (Bromocriptine )" ![]() |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
"Six months of treatment with cabergoline normalized testosterone levels in most cases, thus restoring and maintaining during treatment the capability of normal sexual activity in hyperprolactinemic males" De Rosa M, Zarrilli
S, Vitale G, Di Somma C, Orio F, Tauchmanova' L, Lombardi G, Colao A. ![]() |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
"Cabergoline (Dostinex) significantly improved early morning motor function, and in spite of increased phase shifts and awakenings, patients felt significantly more refreshed in the morning during cabergoline therapy" Hogl B, Rothdach A, Wetter TC, Trenkwalder C.
We suggest that cabergoline (Dostinex) is an adequate adjuvant treatment for Parkinson' disease. There is improvement in motor symptoms (without substantially increased dyskinesias), reduced severity and duration of the wearing-off period, and diminished need for levodopa. Cabergoline can also be useful in the treatment of sleep disturbances associated with advanced Parkinson's disease such as nocturnal akinesia and dystonia. Pastor
P, Tolosa E.
"Treatment with cabergoline (Dostinex) showed higher efficacy and greater safety than other parkinsonian drugs" Baas HK, Schueler P.
"The efficacy of cabergoline (Dostinex) in Parkinson's Desease patients with nocturnal disabilities, restless leg syndrome and augmentation has also been demonstrated. Audits of the clinical efficacy of cabergoline indicate that it is well-tolerated and has an acceptable side effect profile." Marco AD, Appiah-Kubi LS, Chaudhuri KR.
"Our data suggest that cabergoline has neuroprotective effects useful for Parkinson's disease therapy" Lombardi
G, Varsaldi F, Miglio G, Papini MG, Battaglia A, Canonico PL. ![]() |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
"Cabergoline (Dostinex) alleviated RLS
symptoms in 70-90% of patients"
"Low doses of cabergoline (Dostinex) showed effectiveness and safety in patients with moderate to severe RLS, with no appearance of augmentation phenomenon" Zucconi
M, Oldani A, Castronovo C, Ferini-Strambi L.
"An open pilot study shows that
the long-acting dopamine agonist cabergoline is a promising new tool in
the treatment of RLS" <Click here for full research and medical references> ![]() |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
"A single dose of cabergoline (Dostinex) during hospitalization improves the patients' compliance and thus the effect of treatment. Cabergoline (Dostinex)can be used as the drug of first choice for arrest of lactation after abortion during the second trimester of pregnancy." Pavlista D, Calda P, Zivny J.
"Our conclusion is that Dostinex is the most effective agent for prevention of the postpartal lactation given once a day (2 table.) in the first 24 h. post delivery. We read good effect when the medicine was taken twice daily x 1/2 table. for 2 days. Dostinex shows vary good compliance and low rate of relapse of the Lactation"
Bozhinova S, Porozhanova V, Penkov V. 2001 ![]() |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
"We illustrate 2 patients with depression who attained dramatic improvement of energy loss and fatigue when treated with cabergoline (Dostinex)" Takahashi H, Yoshida K, Higuchi H,
<Click here for full research and medical references> |
"In conclusion, the treatment with dopaminergic drugs such as quinagolide and cabergoline, significantly increased the efficacy of somatostatin analogs, and can be used in combined therapy in poorly responsive patients" Marzullo
P, Ferone D, Di Somma C, Pivonello R, Filippella M, Lombardi G, Colao A. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
![]() |
![]() |
![]() |
![]() |
||
The information presented on this site is non professional and non medical You must consult and get your doctor's approval before using any prescription medication
|
||
![]() |